Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Key inclusion criteria include: * Histologically or cytologically confirmed adenocarcinoma of the prostate * Progressive disease per PCWG3 criteria with EITHER: Metastatic CRPC or non- metastatic CRPC (M0CRPC) * For mCRPC: metastatic disease documented by standard or novel imaging techniques * OR for M0CPRC: no evidence of metastatic disease on standard imaging. * OR mHSPC * Surgically or medically castrated, with testosterone levels of \<50 ng/dL. If the patient is medically castrated, continuous dosing with GnRH agonist or antagonist must have been initiated at least 4 weeks prior to randomization and must be continued throughout the study. * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * Able to complete cognitive testing and patient reported outcome surveys in English. * Ability to swallow study medications whole. * Able to provide informed consent.